长春胺联合倍他司汀治疗突发神经性耳聋的临床研究

目的 研究长春胺胶囊联合倍他司汀治疗突发神经性耳聋的临床疗效。方法 纳入太原钢铁（集团）有限公司总医院2021年1月—2022年6月接诊的300例突发神经性耳聋患者，按照数字表法随机分为治疗组和对照，每组各150例。对照组口服盐酸倍他司汀口服液，10 mg/次，3次/d。治疗组在对照组基础上口服长春胺缓释胶囊，30 mg/次，2次/d。两组均治疗14 d。观察两组患者临床疗效，比较治疗前后两组患者听力阈值，C反应蛋白（CRP）水平，血流流变学指标高切黏度、低切黏度、全血黏度与纤维蛋白原。结果 治疗后，治疗组患者总有效率显著高于对照组（97.33%vs 85.33%，P<0.05）。治疗后，两组患者在1、2、4 kHz频率点的听力阈值显著低于治疗前（P<0.05），且治疗组明显低于对照组（P<0.05）。治疗后，两组高切黏度、低切黏度、全血黏度与纤维蛋白原均明显低于治疗前（P<0.05），且治疗组患者低于对照组（P<0.05）。治疗后，两组患者CRP水平均明显低于治疗前（P<0.05），且治疗组患者低于对照组（P<0.05）。结论 长春胺联合倍他司汀方案可更好改善突发神经性耳聋患者的血液黏稠度与CRP水平，增强细胞免疫功能，提高临床疗效。

Clinical study on vincamine combined with betahistine in treatment of sudden deafness

Objective To study the clinical efficacy of vincamine combined with betahistine in treatment of sudden deafness. Methods Patients (300 cases) with sudden deafness in General Hospital of Taiyuan Iron and Steel (Group) Co., Ltd. from January 2021 to June 2022 were divided into treatment group and control group according to the numerical table method, 150 cases in each group. Patients in the control group were po administered with Betahistine Hydrochloride Oral Solution, 10 mg/time, three times daily. Patients in the treatment group were po administered with Vincamine Sustained Release Capsules on the basis of the control group, 30 mg/time, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluation was evaluated, and the hearing threshold, CRP level, hemorheology indexes high shear viscosity, low shear viscosity, whole blood viscosity, and fibrinogen in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (97.33% vs 85.33%, P< 0.05). After treatment, the hearing threshold at 1 kHz, 2kHz, and 4kHz in two groups were significantly lower than those before treatment (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, high shear viscosity, low shear viscosity, whole blood viscosity, and fibrinogen in two groups were significantly lower than those before treatment (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the CRP levels in two groups were significantly lower than before treatment (P < 0.05), and CRP levels in the treatment group patients were lower than that in the control group (P< 0.05). Conclusion Vincristine combined with betastine can better improve blood viscosity and CRP level, enhance cellular immune function and improve clinical efficacy in patients with sudden neurotic deafness.